Acerand Therapeutics (Hong Kong) Ltd. has synthesized compounds acting as EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer.
Unogen Biotech Ltd. has identified triple inhibitors of EGFR (HER1; erbB1), ALK tyrosine kinase receptor and hepatocyte growth factor receptor (HGFR; MET) reported to be useful for the treatment of (non-small-cell) lung cancer.
Casma Therapeutics Inc. has described autophagy targeting chimeras (AUTACs) comprising sequestosome-1 (ubiquitin-binding protein p62; SQSTM1) ligands coupled to an echinoderm microtubule-associated protein-like 4-ALK (EML4- ALK)-targeting moiety via a linker.
Gan & Lee Pharmaceuticals Co. Ltd. has synthesized antibody-drug conjugates comprising a monoclonal antibody covalently linked to exatecan derivatives through a linker reported to be useful for the treatment of cancer.
Solve Therapeutics Inc. has identified antibody-drug conjugates comprising an UC-961 antibody or a tyrosine-protein kinase transmembrane receptor ROR2 (ROR2)-targeting antibody covalently linked to exatecan through a linker reported to be useful for the treatment of cancer.
Tigatx Inc. has been awarded up to $33.5 million in funding by the Advanced Research Projects Agency for Health and a 2-year $2 million Direct to Phase II Small Business Innovation Research grant from the National Cancer Institute.
In tumoral cells, the modulation of the G1/S phases of cell cycle is destabilized by amplification and high expression of cyclin E (CCNE) or by mutation or loss of retinoblastoma 1 (RB1) gene. Cancer cells meeting these characteristics have been sown to be highly sensitive to cyclin-dependent kinase 2 (CDK2) depletion.
Ideaya Biosciences Inc. has nominated IDE-251, a dual KAT6/7 inhibitor targeting 8p11 amplification tumors in breast and lung cancers, as a development candidate. IDE-251 is an equipotent, highly selective, small-molecule dual inhibitor of KAT6 and -7, both of which have been shown to support cancer cell survival.
